HUTCHMED (China) Limited
HCM
$16.10
-$0.01-0.06%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
8/20/2025
-
Globe Newswire
8/19/2025
-
Zacks Investment Research
8/18/2025
-
MarketBeat
8/15/2025
-
Tickeron - Stocks
8/10/2025
-
MarketBeat
8/9/2025
-
MarketBeat
8/9/2025
-
MarketBeat
8/8/2025
-
MarketBeat
8/8/2025
-
Seeking Alpha: Transcripts
8/8/2025
-
SeekingAlpha
8/8/2025
-
GuruFocus
8/8/2025
-
GuruFocus
8/7/2025
-
Globe Newswire
8/7/2025
-
Tickeron - Technical Analysis
8/6/2025
-
Ticker Report
8/2/2025
-
Tickeron - Stocks
8/2/2025
-
Tickeron - Stocks
8/1/2025
-
TipRanks Financial Blog
8/1/2025
-
ETF Channel
7/31/2025
-
Tickeron - Stocks
7/30/2025
-
MarketBeat
7/30/2025
-
Tickeron - Stocks
7/29/2025
-
Tickeron - Stocks
Allianz Asset Management GmbH Lowers Holdings in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM)
7/26/2025
-
MarketBeat
7/26/2025
-
MarketBeat
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Mar 16 and 20 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
852 2121 8200
Address
Cheung Kong Center
48th floor - 2 Queen's Road Central
Hong Kong,
48th floor - 2 Queen's Road Central
Hong Kong,
Country
Year Founded
Business Description
Sector
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong...
more